Alteogen Expands Hybrozyme Partnerships at Jefferies Healthcare Conference

Discussions on expanding application areas with pharmaceutical and biotech firms to be held in London from the 16th to the 19th.

Company to present platform business achievements and mid-to-long-term growth strategies to global investment institutions.

Alteogen is embarking on an initiative to expand partnerships with global pharmaceutical and biotech companies to broaden the application scope of its subcutaneous injection formulation platform, 'Hybrozyme.' The company also plans to meet with global investment institutions to outline the platform's business performance and its mid-to-long-term growth strategy.

Alteogen announced that it will participate in the '2026 Jefferies Global Healthcare Conference,' held in London from the 16th to the 19th. Hosted by the global investment bank Jefferies, the event serves as a venue for pharmaceutical and biotech companies to discuss investment and partnership opportunities. This marks Alteogen's first time attending the conference by invitation.

During the event, the company intends to meet with potential partners interested in Hybrozyme to discuss expanding its application across various therapeutic areas and modalities. Hybrozyme, a technology that converts intravenous drugs into subcutaneous injections, has primarily been utilized for monoclonal antibody-based cancer treatments.

Antibody-Drug Conjugates (ADCs) are also a key area under review for expansion. At the European Society for Medical Oncology (ESMO 2026) annual meeting earlier this year, Alteogen presented the potential of utilizing Hybrozyme for the development of subcutaneous ADC formulations. The company plans to continue these discussions at the conference while seeking new growth engines by engaging with firms that can create synergies with its protein engineering capabilities.

In meetings with global investment institutions, Alteogen will highlight the business achievements and competitiveness of its Hybrozyme platform. It will also present its mid-to-long-term growth roadmap, focusing on securing follow-up pipelines and expanding its development, production, and commercialization capabilities.

Jeon Tae-yeon, CEO of Alteogen, stated, "Through our first participation in the Jefferies conference, we plan to meet directly with prospective partners and global investors to explain our platform's competitiveness and mid-to-long-term growth strategy." He added, "We will identify opportunities to expand the application areas and modalities of our proven Hybrozyme platform and communicate effectively to ensure global investors deeply understand Alteogen's growth potential."

He further noted that face-to-face meetings are crucial opportunities to confirm mutual interests and demands while building trust, emphasizing that the company will focus on translating these interactions into tangible collaborative results.